Kala Pharmaceuticals (KALA) Now Covered by Analysts at Jefferies Financial Group
Jefferies Financial Group assumed coverage on shares of Kala Pharmaceuticals (NASDAQ:KALA) in a report released on Thursday, Marketbeat reports. The firm issued a buy rating and a $15.00 price target on the stock.
KALA has been the topic of a number of other research reports. HC Wainwright restated a buy rating and set a $15.00 price objective on shares of Kala Pharmaceuticals in a research note on Thursday, December 27th. Zacks Investment Research cut Kala Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, January 22nd. BidaskClub upgraded Kala Pharmaceuticals from a hold rating to a buy rating in a research note on Wednesday, February 20th. Wedbush set a $51.00 price objective on Kala Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, January 16th. Finally, JPMorgan Chase & Co. dropped their target price on Kala Pharmaceuticals from $35.00 to $22.00 and set an overweight rating on the stock in a research report on Wednesday, November 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $20.58.
Shares of KALA opened at $8.67 on Thursday. The stock has a market cap of $285.06 million, a price-to-earnings ratio of -3.50 and a beta of 1.73. Kala Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $18.30. The company has a debt-to-equity ratio of 0.30, a quick ratio of 6.27 and a current ratio of 6.34.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Further Reading: Commodities
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.